Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.
Junsheng LiPeicong GeQian ZhangFa LinRong WangYan ZhangDong ZhangWen WangJi-Zong ZhaoPublished in: Neurosurgical review (2021)
Growing evidence has suggested that hyperhomocysteinemia (HHcy) is a risk factor for cerebral infarction. However, the effect of HHcy on postoperative cerebral ischemia is still unclear. We aim to investigate the relationship between HHcy and postoperative ischemia of adult patients with moyamoya disease (MMD). A total of 138 adult patients with MMD were prospectively recruited from July 1 to December 31, 2019. After excluding 14 patients accepting conservative therapy, all 124 patients who underwent surgical treatment were enrolled. Patients were grouped according to postoperative ischemia and HHcy presentation, respectively. Clinical data and laboratory examinations were compared by statistical analyses. Potential risk factors were evaluated by univariate and multivariate logistic regression analysis. Comparing to the normal, patients with postoperative ischemia were higher in serum homocysteine (Hcy) level (P = 0.039) and HHcy ratio (P = 0.035). Furthermore, HHcy was more common in males (P = 0.007) than females. Logistic analysis results showed that HHcy (OR 5.234, 95% CI 1.127-24.315; P = 0.035) was an independent risk factor. HHcy was significantly associated with postoperative ischemia in MMD patients. Our study found that HHcy was correlated to the risk of postoperative ischemia. HHcy can be used as an indicator and a potential therapeutic target for postoperative ischemia in adult patients with MMD. URL: http://www.chictr.org . Unique identifier: ChiCTR2000031412.
Keyphrases
- end stage renal disease
- patients undergoing
- newly diagnosed
- risk factors
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cells
- machine learning
- climate change
- blood brain barrier
- middle cerebral artery
- bone marrow
- case report
- subarachnoid hemorrhage
- deep learning
- cell therapy
- patient reported outcomes
- human health